Measurement issues related to lipoprotein heterogeneity.
about
Statins but not fibrates improve the atherogenic to anti-atherogenic lipoprotein particle ratio: a randomized crossover study.LDL Particle Number and Risk of Future Cardiovascular Disease in the Framingham Offspring Study - Implications for LDL ManagementClustering by plasma lipoprotein profile reveals two distinct subgroups with positive lipid response to fenofibrate therapyAchieving secondary prevention low-density lipoprotein particle concentration goals using lipoprotein cholesterol-based dataAcrolein consumption induces systemic dyslipidemia and lipoprotein modificationSingle-Particle Tracking of Human Lipoproteins.PREVENTION OF ATHEROSCLEROSIS WITH LDL-C LOWERING - LIPOPROTEIN CHANGES AND INTERACTIONS: THE SANDS STUDYThe association of endogenous sex hormones with lipoprotein subfraction profile in the Multi-Ethnic Study of Atherosclerosis.A pro-atherogenic HDL profile in coronary heart disease patients: an iTRAQ labelling-based proteomic approachLipoprotein particle size and concentration by nuclear magnetic resonance and incident type 2 diabetes in women.Using apolipoprotein B to manage dyslipidemic patients: time for a change?Lipoprotein subclasses and endogenous sex hormones in women at midlifeLipoprotein subclasses determined by nuclear magnetic resonance spectroscopy and coronary atherosclerosis in patients with rheumatoid arthritis.Effect of HDL composition and particle size on the resistance of HDL to the oxidation.Effects of fenofibrate on lipid profiles, cholesterol ester transfer activity, and in-stent intimal hyperplasia in patients after elective coronary stentingStronger associations of sagittal abdominal diameter with atherogenic lipoprotein subfractions than waist circumference in middle-aged US white and Japanese men.HIV, HAART, and lipoprotein particle concentrations in the Women's Interagency HIV Study.Morphology and structure of lipoproteins revealed by an optimized negative-staining protocol of electron microscopy.Lipoprotein particle concentrations in children and adults following Kawasaki disease.Clinical implications of discordance between low-density lipoprotein cholesterol and particle number.Lipids, menopause, and early atherosclerosis in Study of Women's Health Across the Nation Heart women.Liposcale: a novel advanced lipoprotein test based on 2D diffusion-ordered 1H NMR spectroscopyHDL surface lipids mediate CETP binding as revealed by electron microscopy and molecular dynamics simulation.Lipoprotein subclass abnormalities and incident hypertension in initially healthy womenHyperhomocysteinemia decreases circulating high-density lipoprotein by inhibiting apolipoprotein A-I Protein synthesis and enhancing HDL cholesterol clearanceHigh-fat meal effect on LDL, HDL, and VLDL particle size and number in the Genetics of Lipid-Lowering Drugs and Diet Network (GOLDN): an interventional study.A clinical comparison of calculated versus direct measurement of low-density lipoprotein cholesterol level.Lipoprotein heterogeneity in persons with Spinal Cord Injury: a model of prolonged sitting and restricted physical activity.Pleiotropic effects on subclasses of HDL, adiposity, and glucose metabolism in adult Alaskan EskimosThe apoB/apoA-I ratio: a strong, new risk factor for cardiovascular disease and a target for lipid-lowering therapy--a review of the evidence.The association between N-terminal pro B-type natriuretic peptide and lipoprotein particle concentration plateaus at higher N-terminal pro B-type natriuretic peptide values: Multi-Ethnic Study on AtherosclerosisClinical importance and therapeutic modulation of small dense low-density lipoprotein particles.Low-density lipoprotein cholesterol versus particle number in middle school children.The effects of extended release niacin on lipoprotein sub-particle concentrations in HIV-infected patientsCritical evaluation of 1H NMR metabonomics of serum as a methodology for disease risk assessment and diagnostics.APOE genotype affects black-white responses of high-density lipoprotein cholesterol subspecies to aerobic exercise trainingThe contribution of ApoB and ApoA1 measurements to cardiovascular risk assessment.An Intervention with Mineral Water Decreases Cardiometabolic Risk Biomarkers. A Crossover, Randomised, Controlled Trial with Two Mineral Waters in Moderately Hypercholesterolaemic Adults.Lipoprotein particle profiles by nuclear magnetic resonance compared with standard lipids and apolipoproteins in predicting incident cardiovascular disease in women.Apolipoprotein B but not LDL cholesterol is associated with coronary artery calcification in type 2 diabetic whites.
P2860
Q21262011-433DF25B-B9FA-4563-B7CB-0204BC9147E9Q21558651-A209F936-FDB0-4BD2-AF53-140A668A5666Q28728567-0F31845E-6690-47B0-8848-6A97828CD41CQ28730849-820891F8-A0EF-4574-8F17-FC9831CC5FE5Q28749663-66BB7659-2554-43C6-B45E-C423B0672BE8Q30708835-1EFB4DC6-E35A-4866-937A-67AFC1279027Q33588399-A4B3CA5E-3B3B-4164-B722-2F40A987FF16Q33596044-EA88536F-CDAA-4141-8DBB-CC0BAAD8BC35Q33655192-83293929-08BE-4091-B8B5-014CE2FBB2C0Q33803431-A44B1266-4F8E-4DC1-9A05-0F54740EE02AQ33820011-B350F80D-5DD5-472D-8B82-9EEE0E21D984Q33825076-CD269D39-4908-4109-9149-8A018F17F1FEQ34037325-3AE243DB-F27D-47C5-AFD8-52EC6C54E6BCQ34198872-C409DB8E-6324-46AE-B737-4B3A0519331CQ34282749-637C1F76-B20D-4ADB-B2BF-8EA358D5FEE3Q34297840-EA459967-5ABB-4142-A14D-E2B8FEB3D3CFQ34355660-BBD889DD-1030-4597-B6FC-334F80742AE4Q34395191-895647B9-F4FE-4DCA-9051-3C8C2CEE7EB2Q34395917-AA2DEE0A-D470-4C16-9AEA-BF0148519DD8Q34757678-E4FFBD00-5A01-431A-94F4-45BC56C38592Q35068678-CF66399C-5076-4BFF-A11D-A403D6698C2FQ35120977-8025FEB7-484B-43CE-91B9-09F44DA6D803Q35144318-AD67BA16-70F2-45DB-889A-354D06E673C5Q35157585-34186903-0D99-42B4-A139-9470899D9967Q35456387-24395DAB-FD6C-4E75-B290-7AB340A63273Q35509384-23016722-385A-4159-ACEE-7E960CA13304Q35681166-9BFFE10F-3257-4A57-BDEF-8E906D09DFDEQ35896788-FADB3D64-BC0F-4128-BE94-B2AB6745F251Q36290006-8DAA073B-F7F8-4F0C-808C-152BF7708A1FQ36455901-F276E1E5-A7B9-44D6-9687-0271B7D0A8FCQ36663488-615FD4B3-BF21-4AA2-9C70-D509ED5D2147Q36675450-D40B4342-60F0-49CB-939A-B51C8268040AQ36859623-DD8AC220-D161-4D9A-9811-A9A4386E925AQ36946694-EAA0F78C-229B-467A-B648-EF1595AB5A68Q37004712-D217F4BC-1CD8-43D4-9C81-754060BF2972Q37074030-DB95BE34-CAD8-4DFF-9C00-5E3EA8AAF1CAQ37107485-7189E851-7C74-4EC0-BF89-37F7543C4F1DQ37133004-5E73C78D-D1ED-4278-9715-D04CFA95D3FEQ37146755-90EFD36C-3138-4FEA-98CE-1705249B36F0Q37267152-6DA6758F-13D3-4F25-A0E3-582EF62C5E83
P2860
Measurement issues related to lipoprotein heterogeneity.
description
2002 nî lūn-bûn
@nan
2002 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Measurement issues related to lipoprotein heterogeneity.
@ast
Measurement issues related to lipoprotein heterogeneity.
@en
Measurement issues related to lipoprotein heterogeneity.
@nl
type
label
Measurement issues related to lipoprotein heterogeneity.
@ast
Measurement issues related to lipoprotein heterogeneity.
@en
Measurement issues related to lipoprotein heterogeneity.
@nl
prefLabel
Measurement issues related to lipoprotein heterogeneity.
@ast
Measurement issues related to lipoprotein heterogeneity.
@en
Measurement issues related to lipoprotein heterogeneity.
@nl
P2093
P1476
Measurement issues related to lipoprotein heterogeneity.
@en
P2093
Elias J Jeyarajah
James D Otvos
William C Cromwell
P304
P356
10.1016/S0002-9149(02)02632-2
P407
P577
2002-10-01T00:00:00Z